Scleroderma Newsroom
ISN News Manager: Jo Frowde
Media Stories
Scleroderma Archive
2016: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
2018 - 2017 - 2016 - 2015

April 2016 Scleroderma News

Cumberland Pharmaceuticals Announces New Program To Develop Vasculan™ For Systemic Sclerosis The U.S. Food and Drug Administration (FDA) has cleared Cumberland's investigational new drug application (IND) for Phase II clinical program for Vasculan™ in patients with systemic sclerosis. Cumberland Pharmaceuticals, 04/27/2016. (Also see Scleroderma Clinical Trials)

Corbus Pharmaceuticals Receives FDA Approval for Open–Label Extension to Its Phase 2 Trial of Resunab for Systemic Sclerosis. Corbus Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) has granted approval for a 12–month open–label extension study of the ongoing Phase 2 clinical trial of Resunab™ for the treatment of diffuse cutaneous systemic sclerosis. Corbus Pharmaceuticals, 04/12/16. (Also see Scleroderma Clinical Trials)

Impact of pulmonary fibrosis (PF) and elevated pulmonary pressures (PHT) on right ventricular (RV) function in patients with systemic sclerosis (SSc). SSc patients show impaired RV function and both pulmonary fibrosis and PHT are independently associated with RV dysfunction. PubMed, Rheumatology (Oxford),2016 Mar;55(3):504-12. (Also see Cardiac (Heart) Involvement and Pulmonary Hypertension)

Research of Lung Fibrosis in Scleroderma (SSc) Reveals High Levels of Antibodies That Correlate with Disease Progression. Circulating antibodies against specific chemokine receptors exist in higher levels in patients with SSc and these antibodies correlate with disease progression and clinical manifestations of the disease. Scleroderma News, 02/25/2016. (Also see Pulmonary Fibrosis)

For Systemic Sclerosis Manifestations in Face and Hands, Fat and Stromal Vascular Fraction Appears Promising. It was suggested that fat and stromal vascular fraction injections (a minimally invasive procedure) are an efficient treatment strategy for systemic sclerosis patients. Scleroderma News, 02/24/2016. (Also see Musculoskeletal Involvement)

Impaired angiogenesis as a feature of digital ulcers (DU) in systemic sclerosis. Our study confirmed the relationship between angiogenic vascular biomarkers and the occurrence of DU. PubMed, Clin Rheumatol, 02/26/2016. (Also see Digital Ulcers)

At–risk systemic sclerosis (SSc) patients can be identified using nailfold videocapillaroscopy ( NVC) a non–invasive imaging technique. The results supported the use of NVC as a routine strategy to evaluate patients with systemic sclerosis and to identify those at higher risks of disease progression and severity. Scleroderma News, 03/08/2016. (Also see Nailfold Videocapillaroscopy)

The investigation of killer cell immunoglobulin–like receptor (KIR) genotyping in patients with systemic lupus erytematosus (SLE) and systemic sclerosis (SSc). The variations of some KIR genes may have a role in the pathogenesis of SLE and SSc and may cause major organ involvement in SLE. PubMed, Clin Rheumatol, 03/09/2016. (Also see Causes of Scleroderma: Natural Killer Cells)

Cellular Therapies in Systemic Sclerosis: Recent Progress. Currently, hematopoietic stem cell transplantation is the only cellular therapy that has demonstrated clinical effects on the immune system, neoangiogenesis, and fibrosis. PubMed, Curr Rheumatol Rep, 2016 Feb;18(2):12. (Also see Stem Cell (Bone Marrow) Transplantation)

Quantitative volumetric assessment of pulmonary involvement in patients with systemic sclerosis (SSc). The percentage of lower lobe volume (PLLV) of the right lung may decrease in SSc patients with interstitial lung disease and the PLLV may be a quantitative parameter indicating damage in the lung. Quantitative Imaging in Medicine and Surgery, 03/09/2016. (Also see Diagnosis of Scleroderma Pulmonary Involvement)

Toll–like receptor 9 (TLR9) signaling is augmented in systemic sclerosis (SSc) and elicits transforming growth factor–ß (TGF–ß)–dependent fibroblast activation. In patients with SSc, mitochondrialDNA and other damage–associated TLR9 ligands in the skin might trigger localized activation of TLR9 signaling, TGF–ß production and consequent fibroblast activation. PubMed, Arthritis Rheumatol, 03/04/2016. (Also see Causes of Scleroderma: Fibroblasts)

Targeting microRNA (miR)–155 to Treat Experimental Scleroderma. Our data suggest the potential of miR–155 silencing as a promising treatment for dermal fibrosis, especially in topical applications. PubMed, Sci Rep, 2016 Feb 1;6:20314. (Also see Skin Fibrosis)

Go to Scleroderma Medical News: March 2016

Giving Assistant
United Way of Central New Mexico
United Way of Snohomish County
See ISN News for recent donors, including Pam Hop, Margaret Roof, Winifred Schillberg, Arnold Slotkin, and Juliet Youkhana. Plus donations in honor of Kim Thwaits, and in loving memory of Marta Marx, Jim Miller, and Arlene Marie Petulla.
Click Here to Donate or Shop
or click on the floating green DONATE button.


TOLL FREE HOTLINE, U.S. and Canada: 1-800-564-7099
Ask for our Free Info Packet by email or postal mail!

SCLERO.ORG is the world leader for trustworthy research, support, education and awareness for scleroderma and related illnesses, such as pulmonary hypertension. We are a service of the nonprofit International Scleroderma Network (ISN), which is a 501(c)(3) U.S.-based public charitable foundation, established in 2002. Meet Our Team, or Volunteer. Donations may also be mailed to:

International Scleroderma Network (ISN)
7455 France Ave So #266
Edina, MN 55435-4702 USA
Email [email protected] to request our Welcome email, or to report bad links or to update this page content. Privacy Policy.

The most important thing in the world to know about scleroderma is!

Donate Now
Copyright 1998-2018, International Scleroderma Network. AKA Scleroderma from A to Z and SCLERO.ORG. All Rights Reserved.